Tegoprubart was well-tolerated, with no drug-related serious adverse events Dose dependent target engagement was demonstrated,…
With Shipa Insights, DevOps and platform teams can instantly verify security compliance and identify policy…
TOKYO, May 31, 2022 – (JCN Newswire) – Yokogawa Electric Corporation and Mitsubishi Heavy Industries,…
TOKYO, May 31, 2022 – (JCN Newswire) – Hitachi High-Tech Corporation today announced the opening…
Panama City, Panama, May 31, 2022 – (ACN Newswire) – MetaMate is a pioneering project…
HONG KONG, May 31, 2022 – (ACN Newswire) – Macau leading gaming equipment supplier Asia…
BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading…
RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it…
David D. Petratis to Retire Following Distinguished 40-Year Career, John H. Stone to Succeed Petratis…
NEW YORK & LONDON–(BUSINESS WIRE)–Genius Sports Limited (“Genius Sports”) (NYSE:GENI), the official data, technology and…
The HPC solution has been successfully applied at a top German auto manufacturer, achieving both…
SANDSIV’s highly secure, hyper-modern, on-premises VoC solution has enhanced Swisscom’s position as a leader in…
GUANGZHOU, China, May 31, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the…
AARHUS, Denmark, May 31, 2022 (GLOBE NEWSWIRE) — STipe Therapeutics (STipe), a company with a…
MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD)…
Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts…
REGULATED INFORMATION Mont-Saint-Guibert, Belgium, 31 May 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and…
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at…
Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make…
FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis Dupixent would be…